Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GERN)
NASDAQ:GERN
GERN Analyst Ratings
Moderate Buy
4 Buy
3 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GERN Stock 12 Month Forecast
Average Price Target
$2.86
▲(95.89% Upside)
| Highest Price Target$5.00 | Average Price Target$2.86 | Lowest Price Target$1.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$1.5
Hold
2.74%
Upside
Reiterated
08/19/25
Leerink Partners
$3
Buy
105.48%
Upside
Reiterated
08/12/25
Geron Inc.: Buy Rating Affirmed Amid Promising Leadership and Growth ProspectsWe hosted a virtual group call with GERN mgmt. The company is making strides toward addressing launch challenges and mgmt. provided some insights into progress they have made to improve brand awareness of Rytelo and increase HCP confidence in prescribing. Notably GERN's new CEO, Harout Semerjian, was in attendance, and we think his background and fresh perspective could help get the Rytelo launch back on track. Overall, the call was pretty straightforward, but a few things stood out. Mgmt. stated they expect to see "steady consistent growth." We've heard this phrase from mgmt. last fall, and it is noteworthy that mgmt. is saying this again now. Mgmt. also reemphasized that their 2Q results (highlighted by 17% Q/Q demand growth) do not reflect the impact of the expanded field effort, which gives optimism into 2H25 and onwards.
Scotiabank
$1.5
Hold
2.74%
Upside
Reiterated
08/07/25
Barclays
$4
Buy
173.97%
Upside
Reiterated
08/07/25
TD Cowen
$4
Buy
173.97%
Upside
Reiterated
08/06/25
Needham
$5
Buy
242.47%
Upside
Reiterated
08/06/25
H.C. Wainwright
―
Hold
―
Reiterated
08/06/25
Goldman Sachs
$1
Sell
-31.51%
Downside
Reiterated
07/18/25
We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.
Wedbush
$7→$6
Buy
310.96%
Upside
Reiterated
05/08/25
Stifel Nicolaus
$4
Buy
173.97%
Upside
Reiterated
03/12/25
B.Riley Financial
$3.5→$2
Hold
36.99%
Upside
Downgraded
02/26/25
Cantor Fitzgerald
$9
Buy
516.44%
Upside
Assigned
11/08/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$1.5
Hold
2.74%
Upside
Reiterated
08/19/25
Leerink Partners
$3
Buy
105.48%
Upside
Reiterated
08/12/25
Geron Inc.: Buy Rating Affirmed Amid Promising Leadership and Growth ProspectsWe hosted a virtual group call with GERN mgmt. The company is making strides toward addressing launch challenges and mgmt. provided some insights into progress they have made to improve brand awareness of Rytelo and increase HCP confidence in prescribing. Notably GERN's new CEO, Harout Semerjian, was in attendance, and we think his background and fresh perspective could help get the Rytelo launch back on track. Overall, the call was pretty straightforward, but a few things stood out. Mgmt. stated they expect to see "steady consistent growth." We've heard this phrase from mgmt. last fall, and it is noteworthy that mgmt. is saying this again now. Mgmt. also reemphasized that their 2Q results (highlighted by 17% Q/Q demand growth) do not reflect the impact of the expanded field effort, which gives optimism into 2H25 and onwards.
Scotiabank
$1.5
Hold
2.74%
Upside
Reiterated
08/07/25
Barclays
$4
Buy
173.97%
Upside
Reiterated
08/07/25
TD Cowen
$4
Buy
173.97%
Upside
Reiterated
08/06/25
Needham
$5
Buy
242.47%
Upside
Reiterated
08/06/25
H.C. Wainwright
―
Hold
―
Reiterated
08/06/25
Goldman Sachs
$1
Sell
-31.51%
Downside
Reiterated
07/18/25
We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.
Wedbush
$7→$6
Buy
310.96%
Upside
Reiterated
05/08/25
Stifel Nicolaus
$4
Buy
173.97%
Upside
Reiterated
03/12/25
B.Riley Financial
$3.5→$2
Hold
36.99%
Upside
Downgraded
02/26/25
Cantor Fitzgerald
$9
Buy
516.44%
Upside
Assigned
11/08/24
Best Analysts Covering Geron
1 Month
xxx
Success Rate
14/27 ratings generated profit
Average Return
+4.90%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 51.85% of your transactions generating a profit, with an average return of +4.90% per trade.
3 Months
xxx
Success Rate
14/27 ratings generated profit
Average Return
+4.27%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 51.85% of your transactions generating a profit, with an average return of +4.27% per trade.
1 Year
2 Years
xxx
Success Rate
10/27 ratings generated profit
Average Return
-4.59%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 37.04% of your transactions generating a profit, with an average return of -4.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GERN Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
14
13
9
8
7
Buy
1
0
0
0
0
Hold
5
6
8
8
11
Sell
0
0
0
2
2
Strong Sell
0
0
0
0
0
total
20
19
17
18
20
Each month's total comprises the sum of three months' worth of ratings.
GERN Financial Forecast
GERN Stock Forecast FAQ
What is GERN’s average 12-month price target, according to analysts?
Based on analyst ratings, Geron Corp’s 12-month average price target is 2.86.
What is GERN’s upside potential, based on the analysts’ average price target?
Geron Corp has 95.89% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GERN a Buy, Sell or Hold?
Geron Corp has a consensus rating of Moderate Buy which is based on 4 buy ratings, 3 hold ratings and 1 sell ratings.
What is Geron Corp’s price target?
The average price target for Geron Corp is 2.86. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $5.00 ,the lowest forecast is $1.00. The average price target represents 95.89% Increase from the current price of $1.46.
The highest analyst price target is $5.00 ,the lowest forecast is $1.00. The average price target represents 95.89% Increase from the current price of $1.46.
What do analysts say about Geron Corp?
Geron Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of GERN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.